NEW YORK (GenomeWeb) – MDxHealth announced today that it has been awarded a US General Services Administration contract to supply its ConfirmMDx prostate cancer test to the Department of Veterans Affairs.
According to the company, the five-year contract provides coverage of ConfirmMDx testing at the Medicare rate for veterans with the VA health system beginning February 1. Additional terms were not disclosed.
ConfirmMDx is an epigenetic tissue-based test for the early detection of prostate cancer, specifically aimed at addressing false-negative biopsy concerns. MDxHealth said that more than 200,000 prostate biopsies are performed within the VA healthcare system annually.
"This contract further underscores ConfirmMDx's clinical value for prostate cancer risk assessment and will be a significant new driver of test volume," MDxHealth CEO Jan Groen said in a statement.
The VA contract follows a series of positive coverage decisions MDxHealth has received for ConfirmMDx recently, including one from Horizon Blue Cross Blue Shield of New Jersey last month.